Ginkgo Bioworks officer proposes $36K share sale

Steve Coen's listed earlier transactions were 752 Class A shares for $5,943.28 on July 17, 2026, and 330 shares for $2,302.47 on August 24, 2026.

Rhea-AI Filing Summary

Ginkgo Bioworks Holdings, Inc. officer Steven P. Coen reported a proposed sale of 2,403 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $36,045.00 and an approximate sale date of October 5, 2026. NYSE is listed as the exchange for the proposed sale, and the reported Class A shares outstanding count is 55,383,808.

Key Figures

Class A shares proposed for sale: 2,403 shares Aggregate market value: $36,045.00 Class A shares outstanding: 55,383,808 shares +4 more

7 metrics

Class A shares proposed for sale 2,403 shares Approximate sale date: October 5, 2026

Aggregate market value $36,045.00 Proposed sale

Class A shares outstanding 55,383,808 shares Reported share-count figure

Shares sold July 17, 2026 752 shares Prior-three-month sales

Amount reported for July 17, 2026 sale $5,943.28 Prior-three-month sales

Shares sold August 24, 2026 330 shares Prior-three-month sales

Amount reported for August 24, 2026 sale $2,302.47 Prior-three-month sales

Key Terms

Restricted Stock Vesting, Rule 144, attorney-in-fact

3 terms

Restricted Stock Vesting financial

"Restricted Stock Vesting | Issuer"

Restricted stock vesting is the timetable and conditions under which shares granted to employees or insiders become fully owned and can be sold, typically requiring continued work or meeting performance goals. It matters to investors because large blocks of shares can become tradable at once, which can change share supply and price, and because vesting aligns insiders’ incentives with the company’s long‑term performance—think of it like a timed unlock that both rewards and locks in key people.

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144"

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

attorney-in-fact regulatory

"as attorney-in-fact for Steve Coen"

An attorney-in-fact is the person or entity given legal authority through a power of attorney to act on behalf of another for specific tasks, such as signing documents, voting shares, or handling transactions. For investors, this matters because it lets a trusted representative make timely decisions or complete paperwork when the owner cannot, much like handing keys to someone to run errands on your behalf—so checks on scope and limits of that authority are important.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Ginkgo Bioworks (DNA) shares did officer Steven P. Coen propose to sell?

Steven P. Coen reported a proposed sale of 2,403 Class A shares through Fidelity Brokerage Services LLC, with an aggregate market value of $36,045.00. The approximate sale date is October 5, 2026, and NYSE is listed as the exchange.

What prior sales did Ginkgo Bioworks (DNA) officer Steven P. Coen report?

The reported transactions were 752 Class A shares for $5,943.28 on July 17, 2026, and 330 Class A shares for $2,302.47 on August 24, 2026.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/05/2026 - 02:04 PM Accepted by SEC EDGAR 10/05/2026 - 02:04 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001977441
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Ginkgo Bioworks Holdings, Inc.
SEC File Number	001-40097
Address of Issuer	27 DRYDOCK AVENUE 8TH FLOOR BOSTON MASSACHUSETTS 02210
Phone	(877) 442-5362
Name of Person for Whose Account the Securities are To Be Sold	Coen Steven P.
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Officer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A	Fidelity Brokerage Services LLC 900 Salem Street Smithfield RI 02917	2403	36045.00	55383808	10/05/2026	NYSE

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A	10/03/2024	Restricted Stock Vesting	Issuer			437	10/03/2024	Compensation
Class A	11/01/2024	Restricted Stock Vesting	Issuer			410	11/01/2024	Compensation
Class A	12/03/2024	Restricted Stock Vesting	Issuer			413	12/03/2024	Compensation
Class A	01/03/2025	Restricted Stock Vesting	Issuer			419	01/03/2025	Compensation
Class A	02/03/2025	Restricted Stock Vesting	Issuer			376	02/03/2025	Compensation
Class A	03/03/2025	Restricted Stock Vesting	Issuer			348	03/03/2025	Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Steve Coen 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	07/17/2026	752	5943.28
Steve Coen 27 Drydock Avenue 8th Floor Boston MA 02210	Class A	08/24/2026	330	2302.47

144: Remarks and Signature

Remarks
Date of Notice	10/05/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	12/15/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/Wade Moss, as a duly authorized representative of Fidelity Brokerage Services LLC, as attorney-in-fact for Steve Coen
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)